Unlocking the potential of
genomic medicine

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
04/20/17Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
PHILADELPHIA, PA -- (Marketwired) -- 04/20/17 -- -- Novel genetic mutations predictive of response to AEVI-001 found in approximately 10% of pediatric ADHD patients -- -- New results clarify a path forward for the continued development of AEVI-001 in ADHD patients and potential future development in other neurodevelopmental disorders -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced updated responder data from a subset of genomically identified patients in the SAGA ... 
Printer Friendly Version
04/12/17Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
PHILADELPHIA, PA -- (Marketwired) -- 04/12/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD (Attention Deficit Hyperactivity Disorder) taking place April 20-23, 2017 in Vancouver, Canada. In addition, the Company will present findings from a non-interventional phenotype/genotype study of nearly 2,000 children diagnosed with AD... 
Printer Friendly Version
03/30/17Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 03/30/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Brian D. Piper, Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT at the Westin New York Grand Central Hotel in New York City. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com or you may us... 
Printer Friendly Version
03/20/17Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
PHILADELPHIA, PA -- (Marketwired) -- 03/20/17 -- Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Clear signal of efficacy and benefit to patients ADHD-RS response rate 70% (p=0.0067 vs placebo) CGI-I re... 
Printer Friendly Version
03/15/17Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 03/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at 3:20 p.m. EDT at the Westin New York Grand Central in New York City. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com ... 
Printer Friendly Version
03/09/17Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
PHILADELPHIA, PA -- (Marketwired) -- 03/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today recent progress and financial results for the three and twelve months ended December 31, 2016. "2016 was an important and produ... 
Printer Friendly Version
02/27/17Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference
PHILADELPHIA, PA -- (Marketwired) -- 02/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at 4:40 p.m. EST at the Boston Marriott Copley Place. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com o... 
Printer Friendly Version
02/21/17Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia
PHILADELPHIA, PA -- (Marketwired) -- 02/21/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). The amendment to the existing agreement with CHOP grants the Company options for long-term exclusive access to certain data and samples from the CAG biobank and certain discoveries in ra... 
Printer Friendly Version
02/15/17Aevi Genomic Medicine Announces 2017 Investor Day
PHILADELPHIA, PA -- (Marketwired) -- 02/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market. The event will be held at the NASDAQ Market Site in New York City on Wednesday, February 22, 2017 with breakfast beginning at 8:30 a.m. Eastern Time and speaker presentations beginning at 9:00 a.m. Eastern Time. The event will include present... 
Printer Friendly Version
02/09/17Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 02/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 10:30 a.m. EST at the Lotte New York Palace, New York, NY. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.... 
Printer Friendly Version
01/31/17Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
PHILADELPHIA, PA -- (Marketwired) -- 01/31/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion Syndrome (22q DS), a rare disorder caused by an abnormality found on the 22nd chromosome. The trial will evaluate the changes in symptoms associated with three neuropsychiatric disorders -- including... 
Printer Friendly Version
01/04/17Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Untitled Document PHILADELPHIA, PA--(Marketwired - Jan 4, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line results expected in Q1 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that enrollment is complete in the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial. All ongoing patients are expected to continue through the follow-up period in order to complete the study. The Company anticipates announcing top-l... 
Printer Friendly Version